



Press Release

Tuesday, October 1, 2014

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531

NSE: STAR

Strides Arcolab clarifies on the Import Alert published on the US FDA website regarding its subsidiary Beltapharm SpA, Italy

Bangalore, October 1, 2014 : In response to the Import Alert published on the US FDA website concerning certain products manufactured by Beltapharm SpA, Italy, Strides Arcolab Limited ('Strides') wishes to clarify that its Italian subsidiary Beltapharm has only one ANDA approved product namely Imiquimod Cream for the US market. This product has been recently launched and is freely available.

The products mentioned in the Import Alert webpage http://www.accessdata.fda.gov/cms_ia/importalert_190.html are manufactured by Beltapharm for an African customer for over 5 years and the Company is working with the US FDA and the African customer, on the circumstances on how these products reached the US market.

Strides further wishes to clarify that it has no role in the distribution of any of these products in the US territory.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products. The Company has 8 manufacturing facilities presence in more than 75 countries in developed and emerging markets. Additional information is available at the Company's website at www.stridesarco.com. For further information, please contact:

Strides Arcolab Limited	<u>PR Consultancy - Weber Shandwick</u>
Mohan Kumar CEO, Pharma +91 80 6784 0748	Kaveri Mandanna: +91 90089 59697 KMandanna@webershandwick.com
Vikesh Kumar +91 80 6784 0827 Kannan N +91 98450 54745	Mahesh Nair: +91 98803 76648 MNair@webershandwick.com

